ARAVIVE (ARAV)
(Delayed Data from NSDQ)
$0.04 USD
0.00 (0.00%)
Updated Jan 26, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
ARAVIVE, INC [ARAV]
Reports for Purchase
Showing records 41 - 60 ( 104 total )
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Dropping Coverage Due to Realignment of Analyst Resources
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
AVB-500 Solidifies Its Pivotal Strategy in PROC and Expands to ccRCC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Going Live in a ccRCC Study Soon and a Ph 3 PROC Trial Start in 1Q21
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
AVB-500 Moves Steadily to Pivotal in PROC With FDA Visibility
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
SITC 2020 Abstract Preview for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Partnership in Place; We Expect More to Come for AVB-500; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
3Q20 Results; Key Study Initiations Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Pivotal PROC Study Planned for 4Q20/1Q21 Start
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Relevant Abstracts at Upcoming EORTC-NCI-AACR Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
2Q20 Results; AVB-500 Moves Forward in PROC and ccRCC on Solid Footing
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
RP2D Set for Ovarian Cancer Phase 2/3 While IgAN Program Gets the Axe
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Nice Feather in the Cap Driving AVB-500 Future; Target Increased to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Key Preclinical Validation at ASCO Enriches AVB-500 Clinical Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J